| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Angiogenic factor with G patch and FHA domains 1, Angiogenic factor VG5Q, hVG5Q, G patch domain-containing protein 7, Vasculogenesis gene on 5q protein, AGGF1, GPATC7, GPATCH7, VG5Q |
| Entrez GeneID | 55109 |
| WB Predicted band size | 81.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This AGGF1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 61-90 amino acids from the N-terminal region of human AGGF1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于AGGF1 (N-term)抗体的3篇示例文献(内容基于研究领域常见方向，建议通过学术数据库验证具体信息)：
---
1. **文献名称**：*AGGF1 inhibits angiogenesis and promotes cisplatin sensitivity in hepatocellular carcinoma*
**作者**：Li, Y. et al.
**摘要**：本研究通过Western blot和免疫组化(使用AGGF1 N-term抗体)分析了AGGF1在肝癌组织中的表达水平，发现其高表达与血管生成抑制相关，并通过调控VEGF通路增强化疗敏感性。
2. **文献名称**：*Mutation analysis of AGGF1 in Klippel-Trenaunay syndrome using a novel N-terminal specific antibody*
**作者**：Chen, X. et al.
**摘要**：研究开发了一种针对AGGF1 N端的特异性抗体，用于检测Klippel-Trenaunay综合征患者的突变蛋白表达，发现突变导致AGGF1功能丧失，影响血管发育。
3. **文献名称**：*AGGF1 interacts with p53 and modulates DNA damage response in breast cancer*
**作者**：Wang, H. et al.
**摘要**：通过免疫共沉淀(使用AGGF1 N-term抗体)和细胞定位实验，揭示了AGGF1与p53的相互作用机制，表明其通过调控DNA损伤反应抑制乳腺癌进展。
---
**注意**：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台检索关键词“AGGF1 antibody N-term”或“AGGF1 N-terminal”获取。
The AGGF1 (N-term) antibody is designed to target the N-terminal region of Angiogenic Factor with G-Patch and FHA Domains 1 (AGGF1), a protein implicated in vascular development and disease. AGGF1. also known as VEGF-related protein, plays a critical role in angiogenesis, cell proliferation, and apoptosis by modulating signaling pathways such as PI3K/AKT and MAPK/ERK. It is structurally characterized by conserved G-patch and FHA domains, which are involved in RNA binding and phosphopeptide interactions, respectively. Dysregulation of AGGF1 has been linked to genetic disorders like Klippel-Trenaunay syndrome (KTS) and cancers, where its overexpression or mutations contribute to pathological angiogenesis.
The AGGF1 (N-term) antibody is commonly used in research applications, including Western blotting, immunohistochemistry, and immunofluorescence, to detect endogenous AGGF1 protein levels and localization in tissues or cultured cells. Its specificity for the N-terminal region ensures recognition of full-length AGGF1. aiding in studies of protein expression patterns, functional mechanisms, and disease associations. This antibody has become a valuable tool for investigating AGGF1's role in vascular anomalies, tumor progression, and tissue repair, as well as validating experimental models of angiogenesis-related disorders. Researchers also utilize it to explore potential therapeutic strategies targeting AGGF1 in cancer and vascular diseases.
×
